Related Experiment Videos
Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study
1Department of Dermatology, Weill Medical College, Cornell University, New York, New York, USA. nssderm@sadickdermatology.com
Summary
Botulinum toxin type B (BTX-B) injections effectively treated glabellar wrinkles in a pilot study, showing rapid results and mild side effects. Further research will explore higher doses for longer-lasting wrinkle reduction.
Area of Science:
- Dermatology
- Cosmetic procedures
- Neuromodulators
Background:
- Botulinum toxin type B (BTX-B) is FDA-approved for cervical dystonia.
- No prior studies investigated BTX-B for glabellar (frown) wrinkles.
- Anecdotal evidence suggests promising efficacy for wrinkle treatment.
Purpose of the Study:
- Assess safety and efficacy of a single BTX-B dose for glabellar lines.
- Document clinical experience with BTX-B in this application.
- Evaluate BTX-B as a novel treatment for glabellar wrinkles.
Main Methods:
- Pilot study involving 30 subjects (28 women, 2 men).
- Injections administered at six sites with 300 U per site, totaling 1800 U.
- Patient and physician assessments conducted at 2 and 4 weeks post-injection.
Main Results:
- All patients responded within 3 days (mean 1.5 days).
- Average wrinkle disappearance score of 2 at 2 and 4 weeks.
- Three patients reported mild adverse events; no severe reactions observed.
Conclusions:
- BTX-B injections demonstrated high efficacy and rapid onset for glabellar wrinkles.
- Mild adverse events and a mean duration of 8 weeks were observed with the tested dose.
- Further studies are warranted to investigate higher doses for potentially longer-lasting effects.